Press Releases

Year

May 31, 2018

Wave Life Sciences to Present at the Jefferies 2018 Healthcare Conference

CAMBRIDGE, Mass. , May 31, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno , M.D., MBA, President and Chief Executive

May 09, 2018

Wave Life Sciences Reports First Quarter 2018 Financial Results and Provides Business Update

CAMBRIDGE, Mass. , May 09, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced financial results for the first quarter ended March 31, 2018 ,

May 07, 2018

Wave Life Sciences Highlights Progress on Hepatic Collaboration with Pfizer

With the designation of five targets, Pfizer nominates the maximum permitted under collaboration Collaboration moving toward candidate selection CAMBRIDGE, Mass. , May 07, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational

Apr 17, 2018

Wave Life Sciences to Present Data on ALS and FTD Programs and on Huntington's Disease at the 2018 American Academy of Neurology Annual Meeting

CAMBRIDGE, Mass. , April 17, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, will present key data on its amyotrophic lateral sclerosis (ALS) and

Apr 10, 2018

Wave Life Sciences and Deep Genomics Form Collaboration to Discover Novel Therapies for Genetic Neuromuscular Disorders

CAMBRIDGE, Mass. and TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, and Deep Genomics Inc.

Apr 05, 2018

Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. , April 05, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno , MD, MBA, President and Chief Executive

Mar 12, 2018

Wave Life Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update

Initiated three clinical trials in 2017 and on track to deliver three additional development programs in 2018 Neurology pipeline growing; candidate in spinocerebellar ataxia type 3 to be named by year end 2018 CAMBRIDGE, Mass. , March 12, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.

Feb 20, 2018

Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders

Wave to receive at least $230 million , including $110 million in upfront cash, $60 million in equity investment and at least $60 million in research support Takeda to receive option to co-develop and co-commercialize investigational therapies in HD, ALS, FTD and SCA3 under a global 50:50

Feb 08, 2018

Wave Life Sciences to Participate in Leerink Partners 7th Annual Global Healthcare Conference

CAMBRIDGE, Mass. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno , MD, MBA, President and Chief Executive